Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Patient selection for left ventricular assist devices.

Lisa Mielniczuk1, Tofy Mussivand, Ross Davies

  • 1University of Ottawa Heart Institute, Ottawa, Ontario, Canada.

Artificial Organs
|February 14, 2004
PubMed
Summary

Mechanical support via left ventricular assist device (LVAD) improves survival for heart transplant candidates. Careful patient selection is crucial for successful LVAD therapy, addressing the gap between transplant needs and availability.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Proteomic markers enhance mortality prediction in heart failure.

European heart journal·2026
Same author

Author Correction to "Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%) [Canadian Journal of Cardiology, Volume 41, Issue 10, Pages 1857-1874. DOI: 10.1016/j.cjca.2025.07.027]".

The Canadian journal of cardiology·2026
Same author

Real-world Persistence on Selexipag for Pulmonary Arterial Hypertension in Canada.

CJC open·2026
Same author

Author Correction for Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%): [Canadian Journal of Cardiology. Volume 41, Issue 10, October 2025, Pages 1857-1874. doi:10.1016/j.cjca.2025.07.027].

The Canadian journal of cardiology·2026
Same author

WITHDRAWN: Corrigendum to Canadian Cardiovascular Society/Canadian Heart Failure Society 2025 Guideline Update for Pharmacologic Management of Heart Failure With Nonreduced Ejection Fraction (LVEF > 40%).: Volume 41, Issue 10, October 2025, Pages 1857-74.

The Canadian journal of cardiology·2025
Same author

The Canadian Heart Failure Society (CHFS) Workforce Committee Report 2024: Addressing the Challenges Facing the Heart Failure Physicians Workforce in Canada CHFS 2024 Heart Failure Workforce Report.

Journal of cardiac failure·2025

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Mechanical Circulatory Support

Background:

  • Mechanical support as a bridge to cardiac transplant is standard care, improving survival and morbidity in selected patients.
  • A significant gap exists between the 30,000 annual global heart transplant waitlist and the 3,500 annual transplants performed.
  • Alternative strategies are needed to reduce mortality and morbidity in this high-risk patient population.

Purpose of the Study:

  • To review cardiac and extracardiac considerations for patient suitability assessments.
  • To highlight the importance of patient selection for left ventricular assist device (LVAD) therapy.
  • To discuss LVADs as a bridge to transplantation strategy.

Main Methods:

  • Review of current literature on LVAD therapy and patient selection criteria.

Related Experiment Videos

  • Analysis of cardiac and extracardiac factors influencing LVAD outcomes.
  • Discussion of best practices for assessing suitability for mechanical support.

    • Main Results:

    • LVAD therapy significantly increases survival rates for patients awaiting heart transplantation.
    • Careful patient selection is the primary factor determining the success of LVAD support.
    • Comprehensive assessment of both cardiac and extracardiac conditions is essential.

    Conclusions:

    • LVADs are a vital tool in managing patients awaiting heart transplantation.
    • Optimizing patient selection is key to maximizing the benefits of LVAD therapy.
    • Further development of alternative strategies is necessary due to transplant limitations.